TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01401036

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biolimus A9 eluting stents
Description: implantation of Biolimus A9 eluting stents

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: uncoated stent
Description: implantation of any uncoated bare metal stents currently available in Japan
Study: NCT03132753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SUPPORT
Description: SUPPORT clients will be offered 12 months of support service with a recovery coach. The recovery coach will guide the client through their recovery, offering guidance and support, while coordinating their treatment services, including support services. The program will provide clients with up to $700 worth of vouchers to cover the cost of additional flexible support services over the 12 months of program enrollment, which will be personalized to fit the needs of the client. These cost vouchers will cover support services, such as housing, employment services, substance use treatment, transportation, childcare, educational or vocational services, or aftercare planning. The costs of each service is determined by the service provider. Further, the recovery coach will assist the client in choosing appropriate services and coordinating/monitoring service completion.
Study: NCT02241161

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plantaricin a - rejuvenating cream
Description: single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plantaricin a - rejuvenating cream
Description: single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plantaricin a - rejuvenating cream
Description: single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plantaricin a - antioxidant serum
Description: single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plantaricin a - antioxidant serum
Description: single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plantaricin a - rejuvenating serum
Description: single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: plantaricin a - rejuvenating serum
Description: single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
Study: NCT03497221

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education intervention
Description: The same description of arm Education intervention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Visual identity campaign
Description: The same description of arm Visual identity campaign.
Study: NCT03271177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7F sheathless Guide Catheter
Description: Transradial PCI will be performed with a 7F sheathless Guide Catheter

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 6F Sheath/Guide Catheter Combination
Description: Transradial PCI will be performed with a 6F Sheath/Guide Catheter Combination
Study: NCT01961921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-TTR02 (patisiran) administered by intravenous (IV) infusion
Study: NCT03416621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral cessation counseling
Description: Standard smoking cessation plus support text messages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral cessation counseling
Description: Standard smoking cessation plus support text messages

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive behavioral cessation counseling
Description: Standard smoking cessation plus support text messages

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counseling and placebo drug intervention
Description: Enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Counseling and active drug intervention
Description: Enhanced cue exposure treatment (lab-based + interactive SMS texting)+ active DCS. In addition to an in-person, screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
Study: NCT05143879

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Citrulline
Description: 3 g/day during 9 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate
Description: 300 mg/day during 9 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate plus Citrulline
Description: 3 g/day of citrulline and 300 mg/day of nitrate during 9 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 g/day during 9 weeks
Study: NCT01281917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
Study: NCT01865578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial direct current stimulation involves the application of weak electric currents to the brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: no electrical stimulation
Study: NCT01128777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy
Description: The CBT group therapy protocol will teach adolescents coping, cognitive restructuring, and affect regulation skills to remediate skills deficits that underlie depression, anxiety, and behavior problems associated with the deployment cycle. Parents will also learn stress management and parenting skills in their own group therapy sessions that occur as the same time as the adolescent group.
Study: NCT02096614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1201 in combination with cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1201 in combination with cyclophosphamide.
Study: NCT03457285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Participants, with a confirmed diagnosis of AS, will be invited to participate. Once participants have provided informed consent, they will be required to complete the outcome measures provided. Participants will be set up to use the online exercise application and educated on its use.~Participants will then have access to videos of suitable exercises or exercise classes to follow and education material on their condition to read. Participants will be able to complete AS specific outcome measures and record their progress. Participants will also have a monthly video call with the senior rheumatology physiotherapist to discuss their exercise programme, symptoms and management. The participants will also record their compliance with their exercise programmes.~After the 6 month pilot period, participants will be required to complete the same outcome measures completed at the start of the study.
Study: NCT01451736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Description: long-acting injectable

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: oral
Study: NCT05389020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Newly developed real-size infant's arm and leg manikin
Description: The control group used conventional manikins made by Nasco; meanwhile, two newly designed real-size manikins were prepared for the intervention group: the right arm and right leg. Real-size manikins were developed based on the mean of anthropometric measurement of 50 Indonesian infants' arms and legs of healthy term neonates born in Dr Cipto Mangunkusumo Hospital. The manikins were made of Thermoplastic Polyurethane (TPU) filament using three-dimensional (3D) printing technology. The manufacturing process was carried out by the Medical Physics Department, Universitas Indonesia.
Study: NCT00839774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole yellow pea flour
Description: Whole pea flour was administered at 50 g/day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fractionated pea flour
Description: Fractionated pea flour was administered according to the level of fiber in whole pea flour treatment. 12 g/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White wheat flour
Description: White wheat flour will be administered at 50 g/day
Study: NCT04155437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Facility Level Interventions
Description: * Intensified counseling on maternal dietary diversity and quality using job aids~* Counseling on purpose of IFA supplementation, managing side effects, and importance of adherence to daily consumption~* Distribution/prescription of IFA tablets at each ANC visit~* Use of pill card/reminders for pregnant women and their spouses~* Monthly IFA tablet stock monitoring to assure sufficient supplies~* Measurement of weight gain during each ANC visit and advise on healthy weight gain~* Checks for functioning scales and use of monitoring sheets~* Intensified counseling on early initiation of breastfeeding and exclusive breastfeeding using job aids~* Reminder on importance of early ANC attendance and 4+ visits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Level Interventions
Description: * Advocacy among community leaders (traditional and religious leaders, local associations, etc.) about ANC~* Gatherings among grandmothers, husbands, and other influencers about ANC and their roles~* Promotion of ANC service utilisation and the importance of early ANC visit during the first trimester.~* Early identification of pregnant women~* Support women's group discussions~* 2-3 home visits per pregnant woman by community health workers (Agent de santé a base communautaire; ASBC) which will include counseling on diet quality, breastfeeding, importance on adherence to daily IFA consumption and side effect management, etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health System Level Interventions
Description: * Training on nutrition interventions during ANC for all ANC providers and community health workers~* Semi-annual supervision by the Regional Health Directorate (Direction Regionale de la Santé; DRS)~* Quarterly supportive supervision of health facility staff by the health district management team~* Monthly supportive supervision of ASBCs~* Monthly review between health facilities and ASBCs~* Training and use of data registers~* Training and use of mother's cards to record up to 8 ANC visits and nutrition services~* Training on data utilization to improve coverage and quality
Study: NCT03388112

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5\*10\^7CFU for 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5\*10\^7CFU for 2 weeks
Study: NCT03165162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Order
Description: randomly assigned orders of 7 bowls of granola, each with a different food label.
Study: NCT02134119

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Echinacea-based dietary supplement
Description: Echinacea-based dietary supplement given at 8,000mg/day or 16,000 mg/day by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic dietary supplement
Study: NCT01454830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored
Description: Individualized on critical indicator (Self-efficacy measure in Sleep Apnea) measured at each intervention delivery period (pre-diagnosis, immediately post-diagnosis, post-CPAP titration, and during week 1 of home CPAP treatment. Intervention components include patient education, preparatory skills training, modification of inaccurate/unrealistic cognitive perceptions of risk, outcome expectations, and treatment self-efficacy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care comparison group will proceed from initial clinical evaluation for OSA, diagnosis by polysomnography, CPAP titration polysomnography, and home CPAP treatment initiation as per current standard of care
Study: NCT02013973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AMH-analysis
Description: At the first visit to the IVF-clinic a blood sample for serum-AMH is taken and frozen for later analysis in the AMH-group. The AMH assay used is the Beckman Coulter AMH Gene II assay. The analysis result will be added to the algorthm deciding what starting gonadotropin dose the patient is having.
Study: NCT01533714

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038 (olokizumab)
Description: Biological/Vaccine: CDP6038 (olokizumab) 100 mg/mL solution for subcutaneous (sc) injection
Study: NCT06257719

Intervention type: OTHER
Intervention: Compare the epidemiological characteristics, clinical presentations, surgical treatments and risk factors for preoperative complications of ALMs between paediatric and adult participants.
Description: Compare the epidemiological characteristics, clinical presentations, surgical treatments and risk factors for preoperative complications of ALMs between paediatric and adult participants.

Intervention type: OTHER
Intervention: Compare the epidemiological characteristics, clinical presentations, surgical treatments and risk factors for preoperative complications of ALMs between paediatric and adult participants.
Description: Compare the epidemiological characteristics, clinical presentations, surgical treatments and risk factors for preoperative complications of ALMs between paediatric and adult participants.
Study: NCT01196689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981 100 mg twice daily for 61/2 days
Description: 100 mg tablets
Study: NCT04228757

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phytoestrogen herbal blend
Description: phytoestrogen herbal blend

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet without active ingredients
Study: NCT02250261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KÄPY
Study: NCT03359798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narcotic counseling script
Description: Script regarding post-cesarean section narcotic use

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Post-partum depression counseling script
Description: Study participants will be read a script of the same length, and much of the same wording as the experimental script. However, this script's content is focused on post-partum depression.
Study: NCT01811862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts). Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts)Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
Study: NCT04106089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended time between vitals check
Description: Participants will have 6 hours protected sleep time (vitals checks moved from every 4 to every 6 hours)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended time between vitals check
Description: Participants will have 6 hours protected sleep time (vitals checks moved from every 4 to every 6 hours)
Study: NCT03080766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine (trade name Dacogen®) is a cytidine deoxynucleoside analogue, which selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation that can result in reactivation of tumor suppressor genes, induction of cellular differentiation or cellular senescence followed by programmed cell death.
Study: NCT02991417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDVAX
Study: NCT03694444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMY-101
Description: C3 complement inhibitor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water for injection
Description: Placebo
Study: NCT01601457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: 90 mcg/kg body weight administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
Study: NCT00284427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin C
Description: IV Vitamin C given 2-3 times a week
Study: NCT01537068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Description: Desvenlafaxine oral dose ranging from 50 to 100 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo pills
Study: NCT02044874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356-lorcaserin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356-lorcaserin hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01289756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Description: clomiphene once 100 mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Description: clomiphene once 100 mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Description: clomiphene once 100 mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Description: clomiphene once 100 mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene and paroxetine
Description: clomiphene 100mg and paroxetine 3x40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene and paroxetine
Description: clomiphene 100mg and paroxetine 3x40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene and paroxetine
Description: clomiphene 100mg and paroxetine 3x40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene and paroxetine
Description: clomiphene 100mg and paroxetine 3x40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene and clarithromycin
Description: clomiphene 100mg and clarithromycin 9x500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene and clarithromycin
Description: clomiphene 100mg and clarithromycin 9x500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene and clarithromycin
Description: clomiphene 100mg and clarithromycin 9x500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene and clarithromycin
Description: clomiphene 100mg and clarithromycin 9x500mg
Study: NCT00312481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate
Description: Split dose, 1-litre solution in the evening prior to colonoscopy and second dose in the morning prior to colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NA picosulfate magnesium citrate
Description: 150 ml solution before 8am on day prior to colonoscopy and 150ml solution 6 to 8 hours later.